Literature DB >> 10811242

Weight gain and antipsychotic medication.

G L Blackburn1.   

Abstract

Antipsychotic-treated patients, who tend to take combinations of psychotropic agents that may cause weight gain, are at special risk for the problems associated with being overweight or obese. Medical and psychiatric examinations should include periodic monitoring for weight change and an obesity assessment for weight-related medical illness. The assessment should involve evaluation of body mass index and waist circumference as well as medical history. Preventative strategies should be undertaken for patients who gain 5 lb (2.3 kg) or more within a 3-year period. A change in antipsychotics may be necessary for overweight patients who are unwilling or unable to lose weight. A treatment plan for overweight or obese patients should include periodic monitoring and recommendations for changes in diet and physical activity. Support groups and adjunct medication may also be helpful. The patient should be reminded of the benefits of even modest weight loss.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811242

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  3 in total

1.  Psychiatric treatment: A risk factor for obesity?

Authors:  Cara F Dosman; Ambikaipakan Senthilselvan; Debra Andrews
Journal:  Paediatr Child Health       Date:  2002-02       Impact factor: 2.253

2.  Assessing obesity and other related health problems of mentally ill Hispanic patients in an urban outpatient setting.

Authors:  David J Hellerstein; Goretti Almeida; Michael J Devlin; Nathaniel Mendelsohn; Stacia Helfand; Dianna Dragatsi; Raquel Miranda; Julie R Kelso; Lucia Capitelli
Journal:  Psychiatr Q       Date:  2007-09

3.  Differences in Aerobic Fitness between Inpatients and Outpatients with Severe Mental Disorders.

Authors:  Helene Daae-Qvale Holmemo; John Christian Fløvig; Jørn Heggelund; Einar Vedul-Kjelsås
Journal:  Front Psychiatry       Date:  2014-08-04       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.